Nabriva Therapeutics has closed a round of funding with €15m, putting its total funds raised at €57.4m since its foundation in 2006.
Nabriva is a Vienna-based biotech company that focuses on developing antibiotics to treat serious infections caused by drug-resistant pathogens. The company spun off from Sandoz, a German generics corporation that develops, produces and distributes pharmaceuticals.
Existing investors Nomura Phase4 Ventures, HBM Partners, The Wellcome Trust, Global Life Science Ventures and Novartis Venture Fund all participated in this latest round.
Dr David Chiswell, CEO of Nabriva Therapeutics, said, “These additional funds extend Nabriva’s cash reach into 2011 and will fund the development of our systemic pleuromutilin programme.”
Copyright © 2009 AltAssets